🇺🇸 FDA
Pipeline program

GTI-2040

2040AML201

Phase 2 mab completed

Quick answer

GTI-2040 for Acute Myeloid Leukemia is a Phase 2 program (mab) at Aptose Biosciences with 1 ClinicalTrials.gov record(s).

Program details

Company
Aptose Biosciences
Indication
Acute Myeloid Leukemia
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials